Up close and personal – The Dr. Kevin Williams story
From a young age, Dr. Kevin Williams looked to his father as a role model. Back in 1952, his father became the third African American physician in Baton Rouge, Louisiana, despite barriers and discrimination faced by Black professionals in the medical field.   “It was a different time,” says Kevin. “When my father first opened his practice, none of the hospitals would give him admitting privileges.”  At his office, Kevin ’s father saw patients on a first come, first served basis. Patients in the area were so eager to see him that they started lining up at 4 o’clock eac...
Source: EyeForPharma - June 7, 2021 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Up close and personal – The Dr. Kevin Williams story
From a young age, Dr. Kevin Williams looked to his father as a role model. Back in 1952, his father became the third African American physician in Baton Rouge, Louisiana, despite barriers and discrimination faced by Black professionals in the medical field.   “It was a different time,” says Kevin. “When my father first opened his practice, none of the hospitals would give him admitting privileges.”  At his office, Kevin ’s father saw patients on a first come, first served basis. Patients in the area were so eager to see him that they started lining up at 4 o’clock eac...
Source: EyeForPharma - June 7, 2021 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

On the journey from pill to platform
As pharma ’s business model increasingly moves beyond the pill towards the patient and the entire therapeutic context, Medical Affairs was already being earmarked as an increasingly pivotal function.  The pandemic-driven changes that have roiled the healthcare sector have been an accelerant to this disruptive trend.  Last year Medical Affairs became an even more essential partner. Healthcare providers (HCPs) have been consulting Medical Science Liaisons (MSLs) for advice and trusted content in greater numbers, increasingly so in a digital context.  There are huge opportunities here for Medical Affai...
Source: EyeForPharma - June 3, 2021 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Optimizing patient Engagement in Trials
Before the pandemic hit, the value for all parties in involving patients as key stakeholders in trial recruitment, design and execution was already becoming clear for pharma businesses, leading to more successful trials for them and better outcomes for patients.   Now, this dynamic has been shown to be even more apparent and important, says Madeline Geday, Director, Global Patient Engagement and Innovation at MSD. “Patients, especially with technology today, understand more than they ever have, and we should as an industry try to give our patients more.   Strong relationships with patient and adv...
Source: EyeForPharma - May 23, 2021 Category: Pharmaceuticals Authors: Joseph Constance Source Type: news

Fixing the broken patient search experience
Try the following exercise: Google ‘My cancer story rocks’ and read about how dog worming medicine is being enthusiastically discussed on YouTube and Facebook as a cancer cure.   Now imagine what else might be popping up in the billion daily healthcare search engine results, which is the first place most people turn the moment they experience symptoms, long before they contact their doctor. The haphazard nature of many searches may prevent patients seeking the right care, induce them to embrace quackery or reject the very medicines which offer the best treatment. “The results patients are ...
Source: EyeForPharma - May 23, 2021 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Including the caregiver in access submissions
While pharma now understands the merit of placing the patient at the centre of all it does, the industry typically gives too little consideration to another important stakeholder - the caregiver. Better products and outcomes are two benefits of doing so. Another is the potential to make a stronger case for a therapy with payers. Because caregivers often prescribe or administer a medicine, they can provide valuable insights to strengthen evidence in access submissions.   “Often, in rare diseases the patient’s abilities are compromised,” says Raquel Cabo, VP of market access and patient services ...
Source: EyeForPharma - May 23, 2021 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

From insight to action in medical affairs
  The context of most human engagement has been limited to the digital space thanks to the current pandemic. Around two thirds of physicians now seek information online, a dramatic increase from the pre-pandemic era.    Clearly on-demand digital consumption of information is fast eclipsing the traditional approach of asking questions of sales reps or MSLs in person, says Kumaran Krishnan, Director of Medical Excellence and Digital Transformation, Teva Pharmaceuticals. “Today, many physicians reach out to digital channels rather than waiting for human interactions to happen.”    And H...
Source: EyeForPharma - May 6, 2021 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

Up close and personal: Reacting in a crisis - The Naji Gehchan story
  Naji Gehchan is no stranger to crises. Growing up in Beirut during the Lebanese civil war, conflict and uncertainty were ongoing realities. And in his early career as a volunteer Red Cross first responder, he became an expert at reacting in emergency situations.  In his current role as Senior Director of Sales at Lilly, that experience is proving to be invaluable. As he leads 150 employees through the pandemic, he continues to rely on the lessons he learned as a first responder. “At the beginning of the pandemic, back in March, with all that was going on at work and personally—I have two litt...
Source: EyeForPharma - March 11, 2021 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Lowering the patient burden in clinical trials
An estimated one in five clinical trials is terminated early, up to 90 per cent fail to hit recruitment targets on time and many investigator sites struggle to enroll enough patients. These are the dispiriting metrics of pharma ’s sub-optimal achievements in trials.  Broadening trial participation and helping ensure participants stick with a trial by lowering the patient burden is one of the keys to moving the dial on the figures above.  The ongoing pandemic is helping here by sharpening pharma ’s focus on having efficient patient recruitment and trial processes in place to make sure they stay the c...
Source: EyeForPharma - March 11, 2021 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Is COVID the gamechanger for decentralized trials?
The shortcomings of the current model for clinical research are well documented. It costs around $26,000 to enroll the average trial participant, of whom one in three typically drops out during the study. This leads to significant delays as only one in seven trials succeeds in enrolling patients in sufficient numbers.    More worryingly, 18% fail to attract a single patient.  The consequences are dire, not just in terms of the $40bn that the pharma industry wastes merely on ‘time costs’ every year. Many patients never learn of clinical research as a viable treatment option, and if they do, their...
Source: EyeForPharma - March 8, 2021 Category: Pharmaceuticals Authors: Ulrich Neumann Source Type: news

The value in measuring the patient experience
This study emphases the value of narrative data in understanding patient experiences and what is most bothersome for them.”  Insights included, for example, the fact that pain in the early cohort was a common factor that had often not been discussed. The project also offered insights into some little understood negative aspects of ‘off’ periods (when symptoms return between medication doses), such as movement symptoms but also non-motor symptoms such as anxiety or fogginess.  “Understanding the language patients use can help improve provider communications and improve outcome measure...
Source: EyeForPharma - February 22, 2021 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Building capacity in digital
The objective,” says Fors, “is to be with the physician anytime, anywhere and we already have thousands of HCPs accessing it.” Content is king And he adds that the onus now is investing in content that adds clinical value, as opposed to overtly commercial marketing type material. “This is one of the big challenges with virtual interaction. Content is king and if you can manage to put updated, high-quality, neutral content on your platform you are a winner because there is value there for the physician.”  The new content model involves a much more collaborative approach in which its...
Source: EyeForPharma - February 22, 2021 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Bringing innovation to rare disease patients in Europe
Why is Biogen focusing on rare diseases?  About 6,000 different rare diseases have been identified to date and these are estimated to affect 30 million people across Europe. It is essential that we collaborate across the medical community, industry, and governments to develop new therapies, explore new technologies and ensure equitable access to treatment. We must innovate across every aspect of treatment to transform the lives of people in these underserved communities.  At Biogen, we have shown that pioneering in neuroscience can change the course of treatment for certain rare diseases. We have transformed the ...
Source: EyeForPharma - February 17, 2021 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

#Icare4Rare campaign launches to raise awareness ahead of Rare Disease Week 2021
For many of the 30 million people affected by rare disease in the EU, lack of effective treatments and discrepancies in access and diagnosis are still common issues. Strong political will, innovation and further cooperation between countries remain vital to improve outcomes and transform their quality of life.To help raise awareness of rare disease, Reuters Events, Biogen and EU40 have collaborated to launch the #Icare4rare campaign to give prominence to Rare Disease Week 2021.Andrea Corazza, Head of Brussels Liaison Office, Public Policy& Government Affairs, Biogen, says: “With this campaign, we want to help put...
Source: EyeForPharma - February 11, 2021 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Joseph Constance
(Source: EyeForPharma)
Source: EyeForPharma - January 6, 2021 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Joesph Constance
(Source: EyeForPharma)
Source: EyeForPharma - January 6, 2021 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Broadening participation in clinical trials: A win for all
The objective is to engage in rea l-world, evidence-based research and bring trials to the local community, where a significant proportion of cancer care is rendered,” he adds.   To help, Cardinal Health ’s real-world evidence and insights teams analyze the real-world data collected from the sites, which can be compared to results from clinical trials to demonstrate the real-world value of therapies.   By bringing these studies to the community, many of the usual challenges are overcome, adds Gajra. These include trial site location (typically academic institutions) and the distances that ...
Source: EyeForPharma - January 6, 2021 Category: Pharmaceuticals Authors: Joseph Constance Source Type: news

Blended and augmented: Reimagining the role of the rep
As pharma tentatively contemplates a post-pandemic future, it is clear that the old sales model has been swept away by this year ’s lockdown and that the field force must adapt.  Industry research from Reuters Events Pharma revealed that 70% of those surveyed expected sales reps ’ face-to-face access to HCPs would not return to thestatus quo ante when pandemic restrictions cease. The research also revealed that the size and disposition of sales teams is under review and smaller field forces look likely.  As the research also made clear, the role of the rep must be rapidly reimagined into more of a d...
Source: EyeForPharma - December 18, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Uncorking the compliance bottlenecks in digital
Making compliance processes fit for the digital age quickly moved from being merely an important problem to a mission critical one this year. In the massive and almost overnight shift to digital engagement since pandemic lockdowns began, the demand for digital content has soared.  The marketeers ’ challenge of supplying content in the quantities and formats HCPs require just when they want it, is matched by the challenge of passing it all through the medical legal review (MLR) process that pharma was only beginning to reconfigure for the new digital realities before the pandemic struck. “MLR as a pro...
Source: EyeForPharma - December 17, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

COVID-19: A data challenge and a catalyst for new insights
  One of the key issues that arose during the pandemic, and arguably a factor that has led to more deaths, has been one of healthcare systems, public health and governments having insufficient or no relevant data on which to base critical decisions. The right data are not in the right place to answer the right questions at the right time. Yet, in the midst of this we have also seen remarkable collaboration on the scientific response to the pandemic, from diagnostics to therapeutic and vaccine research and development. We have learned a lot about the virus since its genome was shared by Chinese researchers in Jan...
Source: EyeForPharma - November 24, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Automation is key in cell and gene therapy manufacturing
The great opportunities of cell and gene therapy (CGT) are self-evident. Life sciences businesses can find a new purpose in a generation of products that could treat or cure millions.  But the CGT industry is early on in its learning curve. Therapies currently priced in the hundreds of thousands or millions of dollars will struggle to find wide payer adoption, however innovative the emerging pricing and payment models may become.  To achieve significant cost savings the sector must move from the manual ad-hoc hospital labs, where the early therapies have been delivered, to scaled-up and far more automated proce...
Source: EyeForPharma - October 30, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

How sustainable is remote health at scale?
With the crisis in healthcare resulting from COVID-19 also come opportunities.  One of these opportunities is the mass adoption of remote healthcare and a new appreciation of its many advantages for healthcare providers and patients alike.  But the pressing question is: Can this innovative model of care weather the post-pandemic future? After all, remote healthcare isn ’t new and unsuccessful attempts have been made to scale it in the past.  The overriding feeling is that remote healthcare is here to stay, having proved its worth to providers, payers, pharma, digital health firms, and patients. So, ...
Source: EyeForPharma - October 28, 2020 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

Digital companions: helping improve patient treatment journeys
Early analysis of the unprecedented shift from traditional face-to-face healthcare towards virtual digital care during the pandemic show that patients have embraced this new care paradigm and expect it to endure beyond 2020.  Patient surveys carried out globally by therapeutics company, Medisafe, during March and April of this year revealed that more than 40% of patients turned to digital health for the first time during lockdown. According to data from Accenture, nine out of ten patients reported that the quality of their virtual care was as good or better than before.  Digital tools, such as video conferencin...
Source: EyeForPharma - October 23, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Racially diverse clinical trials: A new patient-led legacy takes root
The differing health outcomes from COVID-19, depending on sufferers ’ ethnic background, is a salutary reminder of the uneven, and often downright unfair, experience of some ethnic groups when it comes to healthcare.  It further underlines pharma ’s need to do better to make clinical trials more racially diverse and so improve the efficacy of medicines for these under-served groups, and in particular people of Black, Asian and minority ethnicity (BAME).  This is by no means a new problem and, to put it bluntly, pharma ’s approach so far hasn’t worked.  There are many reasons for th...
Source: EyeForPharma - October 15, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Patient engagement: Breaking through in digital
  Face-to-face engagement restrictions during the pandemic made remote engagement the only game in town for pharma and healthcare providers.  The speed at which both have risen to the challenge and adopted digital tools to solve urgent patient care and support needs has been striking. Most pharma players will have relaxed pre-pandemic standard operating procedures to get drugs and treatment advice to patients by any means.  And in a new Reuters Events Pharma survey, almost two thirds (63.2%) of respondents say their patient support programmes are able to meet current remote access conditions.  Now t...
Source: EyeForPharma - October 14, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

COVID-19: The Tipping Point for Rapid Tech Adoption
Every care provider and life sciences business says the same thing: the global pandemic emergency is acting as an unprecedented accelerant that is profoundly changing the way healthcare is delivered and R&D is conducted.    Above all, the experiences of 2020 have expanded our sense of the possibilities for technology to transform our health. We are in a new technological era. “COVID has disrupted our industry,” says Bertrand Bodson, Chief Digital Officer at Novartis. “It has highlighted our strengths and areas we now need to dial up. Healthcare’s digital moment has arrived.&rdquo...
Source: EyeForPharma - October 2, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Up Close and Personal: A Life of Service - The Dr. Dirk Vander Mijnsbrugge Story
Sitting around the kitchen table, Dirk ’s family can’t help but talk about medicine. Dirk, his wife, all three of their children and their spouses are all doctors. With Dirk being the only one to go into industry, he was the target of much teasing. But not anymore. Here’s Dirk’s story.  The youngest son in a lower-middle class family, Dirk Vander Mijnsbrugge was raised to serve others. His parents modelled a life of service; his mom serving their family while his father served their country in the military.    Outside the family, his parents were deeply involved in social service an...
Source: EyeForPharma - October 2, 2020 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

From complexity to clarity in cell and gene therapy
One of the most exciting frontiers in medicine, cell and gene therapies are already offering breakthrough treatments and potential cures in severe genetic diseases and cancer. The innovations continue to advance rapidly, with press releases announcing major breakthroughs on a seemingly monthly basis.  It ’s undoubtedly a good news story but these advances bring with them the challenge of explaining all the exciting, but complex possibilities to patients and caregivers.  The groups that have historically been expected to help keep doctors up to speed cannot be expected to do so in this dynamic environm...
Source: EyeForPharma - September 16, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Australia ’s field force: evolving on fast forward
The pandemic has, it will surprise no one, upended traditional ways of working for pharma ’s Australian field force. “I don't think that we will ever go back to working the way we did pre-COVID, ” says David Grolman, Medical Director at Pfizer Australia and New Zealand.”   But arguably this is less of a revolution than it might first seem. The havoc and disruption it has wreaked has merely accelerated change that was happening anyway, much of it positive, says Matthew Britland, VP of the Australian Pharmaceutical medical and scientific Professionals Association (APPA). “It’s c...
Source: EyeForPharma - September 16, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Survey results: Accelerating digital transformation during COVID-19
COVID-19 has placed the life sciences industry in Europe under extreme pressure, testing it like no other event. Lockdowns have shocked the system and exposed shortcomings, forcing every function to evaluate and adapt its roles and responsibilities almost overnight.  But the pandemic has also accelerated a number of trends, not least the adoption of digital engagement. Pharma has acted on plans that might have taken years to put into effect, pre-pandemic and has, instead, implemented them almost overnight.  While the extent of these changes driven by the pandemic is not yet clear, there is no doubt that they wi...
Source: EyeForPharma - September 4, 2020 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

Paying for cell and gene therapy - Is the future already here?
The ascent of cell and gene therapies over the past few years has been astonishing. And their rise looks unstoppable: By 2025, the FDA expects it will be reviewing 10 to 20 of these transformative drugs per year.    But as we listen to affordability concerns from payers, providers and patients, we ’ve also had to ask, perhaps a bit provocatively, how we can afford to pay for this boom in future cures?  " Without solutions to help payers manage the cost, some of our members may make the choice to exclude coverage " , stated insurer CVS Health earlier in the year in its position paper on ...
Source: EyeForPharma - August 25, 2020 Category: Pharmaceuticals Authors: Ulrich Neumann Source Type: news

Paying for cell and gene therapy - Is the future already here?
The ascent of cell and gene therapies over the past few years has been astonishing. And their rise looks unstoppable: By 2025, the FDA expects it will be reviewing 10 to 20 of these transformative drugs per year.    But as we listen to affordability concerns from payers, providers and patients, we ’ve also had to ask, perhaps a bit provocatively, how we can afford to pay for this boom in future cures?  " Without solutions to help payers manage the cost, some of our members may make the choice to exclude coverage " , stated insurer CVS Health earlier in the year in its position paper on ...
Source: EyeForPharma - August 25, 2020 Category: Pharmaceuticals Authors: Ulrich Neumann Source Type: news

The future of medical congresses
Remember when pharma invested an enormous amount of time, effort and money into attending medical congresses around the world?    In the pandemic-blighted present, where all such global physical events have been put on hold, it seems an age away.    Many organisations – Reuters Events Pharma and ASCO to name but two - took immediate action and successfully transitioned their events to a digital format in record time; others were more risk-averse and chose to postpone events pending more certainty.  So what's going to happen to medical congresses now? Christoph Schmidt, former Global H...
Source: EyeForPharma - August 18, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

The future of medical congresses
Remember when pharma invested an enormous amount of time, effort and money into attending medical congresses around the world?    In the pandemic-blighted present, where all such global physical events have been put on hold, it seems an age away.    Many organisations – Reuters Events Pharma and ASCO to name but two - took immediate action and successfully transitioned their events to a digital format in record time; others were more risk-averse and chose to postpone events pending more certainty.  So what's going to happen to medical congresses now? Christoph Schmidt, former Global H...
Source: EyeForPharma - August 18, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

The future of medical congresses
Remember when pharma invested an enormous amount of time, effort and money into attending medical congresses around the world?    In the pandemic-blighted present, where all such global physical events have been put on hold, it seems an age away.    Many organisations – Reuters Events Pharma and ASCO to name but two - took immediate action and successfully transitioned their events to a digital format in record time; others were more risk-averse and chose to postpone events pending more certainty.  So whither medical congresses now? Christoph Schmidt, former global head of commercial ...
Source: EyeForPharma - August 18, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Webinars: Engaging at scale now and tomorrow
Almost overnight, webinars have become a key resource for pharma during the COVID-19 pandemic.  In May for example, Reuters Events Pharma witnessed the biggest virtual audience of any of its online events, when 3000 attendees joined the webinar on “The new normal of HCP engagement.”    It was just one demonstration of the powerful reach webinars can have. In March webinar use soared across multiple industries – a huge increase in frequency from the same time last year when audiences typically avoided Mondays and Fridays for online events.  The benefits of webinars A chief advan...
Source: EyeForPharma - July 21, 2020 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

Patient centricity: Mind the capacity gap
Pharmaceutical companies and regulators are in need of increasing amounts of input from patients throughout the entire product development lifecycle, from identifying what questions to ask in the earliest stages of research through clinical development to approval.    This usually means partnering with patient organisations and advocacy groups but pharma ’s ambitions here frequently come up against a problem. Very often, both industry and patient organisations are not set up to participate in these processes – with industry lacking systematic processes and patient advocates the required training and ...
Source: EyeForPharma - July 21, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

What patients need right now
  Lockdown is a “prison like” experience, for Londoner Annabelle Ume, who suffers from myalgic encephalomyelitis. “It’s very similar to being trapped in a bunker with no access outside,” says Ume.   Many other fellow sufferers are enduring pandemic enforced isolation without much hope. “They are staying in limbo until help is available and adapting to the worsening of their health conditions,” says Ume. “You just try to make mental peace with it because the physical can’t be addressed at this time.” COPD sufferer John Linnell from Wisconsin i...
Source: EyeForPharma - July 7, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Building the medical affairs organisation of tomorrow
Medical affairs has a lot on its plate. As the pharma model has been shifting from primary-care, blockbuster-drug discovery through to more specialised medicine and gene therapy, the science has naturally become more complicated. ‘  The rise of artificial intelligence and big data means evidence generation now goes far beyond interventional studies, while the environment continues to demand more discussion around value and pricing.    Unwrapping complex science and value makes for a challenging remit for medical – without adding the shifting demands caused by the changing working patterns and g...
Source: EyeForPharma - June 15, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Building the medical affairs organisation of tomorrow
Medical affairs has a lot on its plate. As the pharma model has been shifting from primary-care, blockbuster-drug discovery through to more specialised medicine and gene therapy, the science has naturally become more complicated. ‘  The rise of artificial intelligence and big data means evidence generation now goes far beyond interventional studies, while the environment continues to demand more discussion around value and pricing.    Unwrapping complex science and value makes for a challenging remit for medical – without adding the shifting demands caused by the changing working patterns and g...
Source: EyeForPharma - June 15, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Digital success doesn ’t start with the tech
  We all know that the biggest hurdle for any transformation project is culture. No wonder then that many of us working within digital transformation have hoped to open minds and inspire a new way of working through big, buzzy projects.    There ’s now even a blueprint for this type of innovation: find a tech partner, design a pilot with a trending technology, and ‘signal’ to peers, rivals and shareholders that you’re embracing the future with a flashy press release.   But when we sat down with Dan Rothman the Chief Digital Officer, Dainippon Sumitomo Pharma and Milind Ka...
Source: EyeForPharma - May 28, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Digital success doesn ’t start with the tech
  We all know that the biggest hurdle for any transformation project is culture. No wonder then that many of us working within digital transformation have hoped to open minds and inspire a new way of working through big, buzzy projects.    There ’s now even a blueprint for this type of innovation: find a tech partner, design a pilot with a trending technology, and ‘signal’ to peers, rivals and shareholders that you’re embracing the future with a flashy press release.   But when we sat down with Dan Rothman the Chief Digital Officer, Dainippon Sumitomo Pharma and Milind Ka...
Source: EyeForPharma - May 28, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news

Digital success doesn ’t start with the tech
  We all know that the biggest hurdle for any transformation project is culture. No wonder then that many of us working within digital transformation have hoped to open minds and inspire a new way of working through big, buzzy projects.    There ’s now even a blueprint for this type of innovation: find a tech partner, design a pilot with a trending technology, and ‘signal’ to peers, rivals and shareholders that you’re embracing the future with a flashy press release.   But when we sat down with Dan Rothman the Chief Digital Officer, Dainippon Sumitomo Pharma and Milind Ka...
Source: EyeForPharma - May 28, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news